- Home
- REPX vs COGT Comparison
REPX vs COGT Comparison
Compare REPX & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPX
- COGT
- Stock Information
- Founded
- REPX 2016
- COGT 2014
- Country
- REPX United States
- COGT United States
- Employees
- REPX N/A
- COGT N/A
- Industry
- REPX Oil & Gas Production
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- REPX Energy
- COGT Health Care
- Exchange
- REPX Nasdaq
- COGT Nasdaq
- Market Cap
- REPX 608.2M
- COGT 545.3M
- IPO Year
- REPX N/A
- COGT 2018
- Fundamental
- Price
- REPX $25.84
- COGT $4.37
- Analyst Decision
- REPX Strong Buy
- COGT Buy
- Analyst Count
- REPX 1
- COGT 7
- Target Price
- REPX $47.00
- COGT $14.17
- AVG Volume (30 Days)
- REPX 106.4K
- COGT 1.7M
- Earning Date
- REPX 05-07-2025
- COGT 05-06-2025
- Dividend Yield
- REPX 5.86%
- COGT N/A
- EPS Growth
- REPX N/A
- COGT N/A
- EPS
- REPX 4.26
- COGT N/A
- Revenue
- REPX $410,181,000.00
- COGT N/A
- Revenue This Year
- REPX $7.75
- COGT N/A
- Revenue Next Year
- REPX $2.95
- COGT N/A
- P/E Ratio
- REPX $6.07
- COGT N/A
- Revenue Growth
- REPX 9.37
- COGT N/A
- 52 Week Low
- REPX $21.98
- COGT $3.72
- 52 Week High
- REPX $37.55
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- REPX 45.25
- COGT 34.56
- Support Level
- REPX $21.98
- COGT $4.12
- Resistance Level
- REPX $24.72
- COGT $5.09
- Average True Range (ATR)
- REPX 1.89
- COGT 0.54
- MACD
- REPX -0.04
- COGT -0.02
- Stochastic Oscillator
- REPX 48.13
- COGT 23.90
About REPX Riley Exploration Permian Inc.
Riley Exploration Permian Inc is engaged in the business of exploration for and production of oil and natural gas. The company operations are in Kansas Properties, and Tennessee Properties, among others.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.